Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMA203CD4
- Development stage
- Unknown
- Lead developer
- Immatics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IMA203CD4 is an autologous T-cell receptor (TCR) engineered T-cell therapy developed by Immatics. It is specifically designed to utilize CD4+ T cells that have been engineered to express a TCR targeting a peptide derived from the PRAME (Preferentially expressed Antigen in Melanoma) protein, presented by HLA-A*02:01. While many TCR-T therapies focus on CD8+ cytotoxic T cells, IMA203CD4 aims to leverage the helper and direct cytotoxic functions of CD4+ T cells to enhance the anti-tumor response and improve durability in patients with PRAME-expressing solid tumors. This candidate is part of Immatics' ACTengine platform and is being evaluated in clinical trials for various solid cancers.
- Other names
- IMA203 CD4-Immatics-PRAME-cell therapy-solid cancersIMA-203 CD4-Immatics-PRAME-cell therapy-solid cancersIMA 203 CD4-Immatics-PRAME-cell therapy-solid cancers
02
Targets
PRAME peptide–HLA complex
Beyond the preview
Go deeper on IMA203CD4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMA203CD4.